- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00002232
A Study of GENEVAX-HIV, a Possible Vaccine
GENEVAX-HIV (APL 400-003), a Candidate DNA Vaccine: A Pilot Study of GENEVAX-HIV Given by Intramuscular or Intradermal Administration in HIV Seronegative Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20307
- Walter Reed Army Institute of Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Patients must have:
- Good health.
- Ability to understand the basis of HIV transmission and other common sexual and blood-borne infections.
- The following parameters within normal range:
- Hematopoietic:
- total white blood cell, lymphocyte, granulocyte, and platelet count, hemoglobin and hematocrit.
- Renal:
- BUN and creatinine, urinalysis.
- Hepatic:
- total serum bilirubin.
- Endocrine/Metabolic:
- Serum calcium, serum glucose, total serum CPK.
- Immunologic:
- total serum immunoglobulin and absolute CD4 count.
- Hepatitis B and Hepatitis C negative.
- Urinalysis:
- Normal screen with dipstick for esterase and nitrite.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- HIV-seropositive status.
- Any positive result for anti-DNA antibodies considered of potential clinical significance as measured by anti-DNA antibody and/or anti-nuclear antibody (ANA) assays.
- Any condition which, in the opinion of the principal investigator, might interfere with completion of the study or evaluation of the results.
- Known hypersensitivity to bupivacaine or any amide-type local anesthetic (such as lidocaine, dibucaine, mepivacaine, and prilocaine) or a history of anaphylaxis or other serious adverse reactions to vaccines.
Concurrent Medication:
Excluded:
Any medication which may affect immune function with the exception of low doses of nonprescription-strength NSAIDS, aspirin, or acetaminophen for acute conditions such as headache or trauma.
Patients with the following prior conditions are excluded:
- HIV-seropositive.
- Known or suspected history of impairment or abnormality in immune functioning.
- Exposure to potentially-infective HIV fluids within the prior 6 months or tested positive for HIV at any time.
- History of any prior disease or therapy which would affect immune function including:
- Prior malignancy, except curatively-treated basal cell or squamous cell carcinoma in situ of the cervix.
- Immunodeficiency or autoimmune disease.
- Acute infection or a recent (within 6 months) history of chronic infection.
- History of serious allergic reaction to any substance requiring hospitalization or emergent medical care (e.g., Stevens-Johnson syndrome, bronchospasm, or hypotension).
Prior Medication:
Excluded:
Cytotoxic chemotherapy that may affect immune function.
Prior Treatment:
Excluded:
- Previous immunization with any experimental vaccines directed against HIV or receipt of any experimental agent within 30 days prior to enrollment.
- Receipt of any blood products or immunoglobulin within 6 months prior to enrollment.
- Exposure to live attenuated vaccines within 60 days of study.
- Radiotherapy that may affect immune function.
Risk Behavior:
Excluded:
- Active drug or alcohol abuse or uncontrolled (unstable) psychiatric disorders which, in the opinion of the investigator, would interfere with study participation.
- Higher- or intermediate-risk sexual behavior (AVEG criteria)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Masking: Double
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Merlin Robb
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 005
- 400-003-05
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on APL 400-003
-
National Institute of Allergy and Infectious Diseases...CompletedAcquired Immunodeficiency Syndrome | HIV InfectionUnited States
-
Wyeth-Lederle VaccinesCompletedHIV Infections | HIV SeronegativityUnited States
-
ApollonCompleted
-
Jiangsu Yahong Meditech Co., Ltd aka AsierisNot yet recruiting
-
Asieris Pharmaceuticals (AUS) Pty Ltd.Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
Shenzhen NewDEL Biotech, Co., LtdShenzhen Innovation Center for Small Molecule Drug Discovery Co., Ltd.Not yet recruiting
-
Apellis Pharmaceuticals, Inc.CompletedNeovascular Age-Related Macular DegenerationUnited States, Australia
-
Longbio PharmaActive, not recruitingChronic Spontaneous UrticariaChina
-
University of North Carolina, Chapel HillNaturex SACompleted